Arcturus Therapeutics Holdings Inc. (ARCT) Stock Forecast
ARCT analyst forecast
as of October 17, 2026- Analyst consensus
- Strong buy 4.62 / 5 from 13 analysts
- Price target
- $23.80 average of analyst targets
- Upside to target
- +130.2% from the latest close
- Next earnings
- November 9, 2026 EPS estimate $-0.60
- 52-week range
- $5.53 – $23.16
ARCT analyst ratings
13 analystsNumber of analysts at each rating.
ARCT price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
ARCT earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.68 | −$0.92 | −$0.29 | −$0.49 | −38.9% | 10 |
| Current fiscal year (2026) | −$3.45 | −$4.58 | −$2.95 | −$2.40 | −43.9% | 10 |
| Next fiscal year (2027) | −$3.70 | −$4.89 | −$1.99 | −$3.45 | −7.2% | 10 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
ARCT revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $8.0M | $2.0M | $16.0M | −53.1% | 13 |
| Current fiscal year (2026) | $18.6M | $8.3M | $33.0M | −77.3% | 13 |
| Next fiscal year (2027) | $28.8M | $3.0M | $127.8M | +54.5% | 13 |
ARCT EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
ARCT revenue: reported and forecast
ARCT EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.88 | −$0.67 | −$0.67 | −$0.67 | −$0.68 | −22.5% | 0 up · 1 down |
| Current fiscal year (2026) | −$3.86 | −$3.37 | −$3.42 | −$3.42 | −$3.45 | −10.4% | 0 up · 1 down |
| Next fiscal year (2027) | −$4.02 | −$3.78 | −$3.61 | −$3.62 | −$3.70 | −8.0% | 0 up · 2 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
ARCT earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; ARCT beat in 10 of 12.
What analysts expect from ARCT
13 analysts cover Arcturus Therapeutics; their consensus rating is strong buy (4.62 on a 1–5 scale, where 5 is a strong buy). The average price target is $23.80, 130.2% above the latest close of $10.34. Analysts expect earnings of −$3.45 per share for 2026, −43.9% from a year earlier. For 2027 the average estimate is −$3.70 per share on revenue of $28.8 million. Arcturus Therapeutics beat the EPS estimate in 10 of the last 12 quarters.
Related: ARCT income statement, ARCT key metrics, ARCT chart. See the ARCT stock overview for the latest quote and news.
ARCT forecast FAQ
What is Arcturus Therapeutics's price target?
The average analyst price target for Arcturus Therapeutics is $23.80, 130.2% above the latest close of $10.34.
Is Arcturus Therapeutics a buy, hold or sell?
Of 13 analysts covering Arcturus Therapeutics, 10 rate it a strong buy, 1 a buy, 2 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Arcturus Therapeutics's EPS forecast?
Analysts forecast −$3.45 per share for 2026 (range −$4.58 to −$2.95); for 2027 the estimate is −$3.70.
What is Arcturus Therapeutics's revenue forecast?
The average revenue estimate for 2026 is $18.6 million, growth of −77.3%; for 2027 it is $28.8 million.
When does Arcturus Therapeutics report earnings?
Arcturus Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 9, 2026 after the market closes; the EPS estimate is $-0.60.
Does Arcturus Therapeutics usually beat earnings estimates?
Arcturus Therapeutics reported EPS at or above the analyst estimate in 10 of the last 12 quarters.